Signature Equity Partners’s Sanofi SNY Stock Holding History

Signature Equity Partners’s Portfolio SNY Stock Details SNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.66K	Buy	203 +32	+19%	+$1.43K	﹤0.01%	855
2026 Q1	$8.24K	Sell	171 -1	-0.6%	-$47	﹤0.01%	847
2025 Q4	$8.34K	Buy	+172	New	+$8.53K	﹤0.01%	857

Other funds holding SNY

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

MIP

Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Signature Equity Partners's SNY Position: Q2 2026 in Review

Signature Equity Partners increased its Sanofi (SNY) stake by 19% in Q2 2026, buying an estimated $1.43K and bringing the position to 203 shares worth $8.66K. The position accounts for ﹤0.01% of the portfolio, ranked #855.

Signature Equity Partners first reported a position in SNY in Q4 2025 and has held it in 3 quarters since. 714 funds tracked by Wall St. Rank hold SNY as of Q2 2026.

Signature Equity Partners held 203 shares of Sanofi worth $8.66K as of Q2 2026.
Signature Equity Partners bought 32 Sanofi shares in Q2 2026, an estimated $1.43K.
Sanofi made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #855 holding.
Signature Equity Partners first reported a position in Sanofi in Q4 2025 and has held it in 3 quarters since.
714 funds tracked by Wall St. Rank held Sanofi as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.